Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
To view or add a comment, sign in The European Association for the Study of Obesity (EASO) has released new guidance recommending #Semaglutide and #Tirzepatide as first-line medications for obesity and most of its related complications
Don't be most founders
Potential side effects include: Vomiting and nausea Stomach cramps Dizziness Dehydration Bowel perforation Infection Depletion of probiotics, sodium and potassium Kidney damage Some people think a colon cleanse can help with bloating or constipation
Similar Benefits: Comparable to Semaglutide, including improved blood pressure, blood sugar levels, and cardiometabolic risk factors
For example, a patient who was using Ozempic for diabetes might reach their goal but still need weight management support, and their doctor might transition them to Wegovy
